Subject(s)
Aortic Dissection , Female , Humans , Aortic Aneurysm/surgery , Aortic Aneurysm/diagnostic imaging , Aortic Aneurysm, Thoracic/surgery , Aortic Aneurysm, Thoracic/diagnostic imaging , Aortic Dissection/surgery , Aortic Dissection/diagnostic imaging , Aortic Valve/surgery , Aortic Valve/diagnostic imaging , Blood Vessel Prosthesis Implantation/methods , Blood Vessel Prosthesis Implantation/instrumentation , Heart Valve Prosthesis , Treatment Outcome , Aged, 80 and overABSTRACT
Non-small cell lung cancer (NSCLC) represents the most common and fatal type of primary lung malignancies. NSCLC is often diagnosed at later stages and requires systemic therapies. Despite recent advances in surgery, chemotherapy, and targeted molecular therapies the outcomes of NSCLC remain disproportionately poor. Immunotherapy is a rapidly developing area in NSCLC management and presents opportunities for potential improvements in clinical outcomes. Indeed, different immunotherapeutics have been approved for clinical use in various settings for NSCLC. Their promise is especially poignant in light of improved survival and quality of life outcomes. Herein, we comprehensively review emerging NSCLC therapeutics. We discuss the limitations of such strategies and summarize the present status of various immunotherapeutic agents in key patient populations. We also examine the data from ongoing studies in immunotherapy and consider future areas of study, including novel inhibition targets, therapeutic vaccination, tumor genome modification, and improvements to drug delivery systems.
